Abstract
Objectives We investigated the epidemiology and impact on mortality of antimicrobial resistance (AMR) in cancer patients with bacteraemia at Oxford University Hospitals (OxUH), UK, and Oslo University Hospital (OsUH), Norway, during 2008-2018.
Design Historical cohort study.
Setting Regional hospital trusts with multiple sites in OxUH and OsUH.
Methods Patients with cancer and blood cultures positive for one of six pathogen groups during a hospital stay within three years following their first cancer diagnosis were followed for 30 days after their first bacteraemia episode. We determined the number of cases and the proportion of infections with an AMR phenotype. Excess mortality and the population-attributable fraction (PAF) due to AMR were estimated by contrasting observed mortality at the end of follow-up with an estimated counterfactual scenario where AMR was absent from all bacteraemias, using inverse probability weighting.
Main outcome measure 30-day all-cause mortality following the first bacteraemia episode.
Main exposure measure A resistant phenotype of the causative pathogen.
Results The study included 1929 patients at OxUH and 1640 patients at OsUH. The highest resistance proportions were found for vancomycin-resistance in enterococci (85/314, 27.1%) and carbapenem-resistance in Pseudomonas aeruginosa (63/260, 24.2%) at OxUH, and third-generation cephalosporin-resistance in Escherichia coli (62/743, 8.3%) and Klebsiella pneumoniae (14/223, 6.3%) at OsUH. Observed mortality for all infections was 26.4% at OxUH, with an estimated counterfactual mortality without AMR of 24.7%, yielding an excess mortality of 1.7% (95% CI: 0.8-2.5%). The PAF was 6.3% (95% CI: 2.9-9.6%), meaning an estimated 32 of 509 deaths could be attributed to AMR. Limited events at OsUH precluded a similar estimate.
Conclusions Despite modest excess mortality from AMR at OxUH and limited data at OsUH, the considerable mortality attributable to resistance represents a challenge with the potential to escalate, especially in the context of worsening global trends in resistance.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by a grant from the South-Eastern Norway Regional Health Authority trust (grant number 2021013), and by the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Healthcare Associated Infections and Antimicrobial Resistance at Oxford University in partnership with the UK Health Security Agency (NIHR200915), and the NIHR Biomedical Research Centre, Oxford. DWE is a Big Data Institute Robertson Fellow. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, the Department of Health or the UK Health Security Agency. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Research Ethics Committee, Health Research Authority, and Confidentiality Advisory Group (19/SC/0403, 19/CAG/0144) gave ethical approval for the work involving the Infections in Oxfordshire Research Database (IORD). The Regional Ethics Committee of South East Norway (240258) and the Data Protection Officer at OsUH (21/06874) gave ethical approval for the work involving Norwegian registry data.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data analysed are not publicly available as they contain personal data. Oxfordshire data are available from the Infections in Oxfordshire Research Database (https://oxfordbrc.nihr.ac.uk/research-themes-overview/antimicrobial-resistance-and-modernising-microbiology/infections-in-oxfordshire-research-database-iord/), subject to an application and research proposal meeting on the ethical and governance requirements of the Database. Data from the Norwegian health registries can be accessed via https://helsedata.no/en/ following an application process, with guides available on the site detailing the requirements and steps for access.
